Study of tebentafusp and radioembolization for uveal melanoma that spread to the liver
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your uveal melanoma must have spread mostly to the liver.
- You must have a specific genetic marker called HLA-A*02:01 (a blood test will show this).
- You must be 18 years or older and able to give informed consent.
- You must be well enough to be up and about (ECOG score 0 or 1).
- Your liver and blood test results must meet safety limits (like bilirubin, liver enzymes, blood cell counts).
- You cannot have had previous radiation or other treatments to the liver for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
This trial tests if immune cells taken from a liver tumor can be given back to fight metastatic melanoma. It is for people with stage IV uveal or cutaneous melanoma that has worsened after standard treatments.
This trial tests a drug called tebentafusp before surgery for uveal melanoma that has spread to the liver. The goal is to see if giving the drug first can shrink the tumors and make surgery more effective.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.